Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATYR0101
- Development stage
- Preclinical
- Lead developer
- aTyr Pharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
ATYR0101 is a novel fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS), developed by aTyr Pharma. It acts as an anti-fibrotic agent by binding to latent transforming growth factor beta binding protein 1 (LTBP-1), inducing apoptosis in myofibroblasts—key cells responsible for the progression of fibrosis. This mechanism offers a differentiated approach compared to current therapies, with preclinical studies demonstrating significant reduction in fibrotic markers and tissue scarring in models of lung and kidney fibrosis. The drug is currently at the IND-enabling stage for pulmonary fibrosis and has shown potential for broader application across multiple fibrotic diseases[2][3][4][5][6].
- Other names
- Aspartyl-tRNA synthetase fragment
Beyond the preview
Go deeper on ATYR0101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATYR0101.